ERBB2 and breast cancer: The study used double-negative (ER−/PR−/HER2+) and triple-negative (ER−/PR−/HER2−) breast cancer pre-clinical mouse models with tumors developed either orthotopically (double-negative, MDA-MB-435) or as xenograft (triple-negative, MDA-MB-231).